Title

Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging".

Authors

Politi, Letterio S.; Pessina, Federico; Simonelli, Matteo; Navarria, Pierina

Abstract

Imaging parameters of high-grade gliomas in relation to the MGMT promoter methylation status: The CT, diffusion tensor imaging, and perfusion MR imaging. In diffuse malignant gliomas, the methylation of the promoter of the O6-methylguanine-DNA methyltransferase (MGMT) gene is the most significant predictor of response to chemotherapy, and one of the most robust prognostic factors.1 The MGMT gene encodes for a cellular protein that is able to repair the lethal cross-links between adjacent strands of DNA caused by alkylating agents, such as temozolomide (TMZ).

Subjects

WORLD Health Organization; MAGNETIC resonance imaging; TUMOR grading; CONTRAST-enhanced magnetic resonance imaging; BRAIN tumors; METHYLATION; GLIOMAS; WORLD health; CENTRAL nervous system tumors

Publication

Journal of Magnetic Resonance Imaging, 2021, Vol 54, Issue 1, p237

ISSN

1053-1807

Publication type

Academic Journal

DOI

10.1002/jmri.27594